Together, they address different aspects of the healing process
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes
For some reason one of the three arrangements possible for the other two structures could have been less stable or harder to prepare and had simply not yet been synthesized
According to a commenter, even if CMS moved to market-based weights, it would still need cost data for other purposes (outlier payments, new technology add-on payments, etc.) and thus, hospitals would shoulder additional reporting duties rather than any offsetting reduction
Diabetes medications (e.g., insulin or sulfonylureas): These may cause low blood sugar when combined with CagriSema, attentive monitoring would be recommended
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
